진매트릭스
Financials
Valuation Metrics
진매트릭스's Market Cap is ₩295B. At end of 2025 it was ₩501B. Ranked #2095 of 2,436 in KR market (top 86%), #1336 of 1,649 on KOSDAQ (top 81%), #217 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 29.47B KRW | KR#2,095/2,436 Sec#217/234 |
| Revenue | 10.67B KRW | KR#2,279/2,436 Sec#174/234 |
| Net Income | -1.27B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 27.04B KRW | KR#2,339/2,436 Sec#224/234 |
| Net Assets | 17.25B KRW | KR#2,312/2,436 Sec#218/234 |
| Employees | 67 | KR#1,893/2,436 Sec#164/234 |
| Value | ||
| P/B | 1.71x | KR#1,856/2,436 Sec#133/234 |
| P/S | 2.76x | KR#1,973/2,436 Sec#117/234 |
| FCF Yield | 4.16% | KR#916/2,436 Sec#51/234 |
| Profitability | ||
| ROE | -7.36% | KR#1,825/2,436 Sec#138/234 |
| ROA | -4.69% | KR#1,878/2,436 Sec#141/234 |
| Op. Margin | -6.73% | KR#1,905/2,436 Sec#128/234 |
| Revenue Growth | 0.89% | KR#1,384/2,436 Sec#132/234 |
| Financial Health | ||
| Debt Ratio | 156.73% | KR#1,278/2,436 Sec#144/234 |
| Total Debt | 3.60B KRW | KR#1,834/2,436 Sec#177/234 |
| FCF | 1.23B KRW | KR#1,133/2,436 Sec#82/234 |
| Cash | 2.17B KRW | KR#2,230/2,436 Sec#214/234 |
| Current Ratio | 4.45x | KR#353/2,436 Sec#65/234 |
| Performance | ||
| 1Y Return | -45.37% | KR#2,000/2,436 Sec#181/234 |
| 1M Return | 4.48% | KR#858/2,436 Sec#68/234 |
| From 52W High | -62.32% | KR#1,861/2,436 Sec#156/234 |
| 1Y MDD | -59.51% | KR#1,386/2,436 Sec#110/234 |
| Trading | ||
| Volume | 101,821 shares | KR#1,883/2,436 Sec#182/234 |
| Foreign Own. | 1.92% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -62 KRW | KR—/2,436 Sec—/234 |
| BPS | 864 KRW | KR#2,311/2,436 Sec#211/234 |
Company Info
Genematrix, established in 2000 and headquartered in Seongnam-si, Gyeonggi-do, was founded to develop pharmaceuticals and diagnostics using biotechnology, listing on KOSDAQ in 2009. The company develops and sells medical diagnostic reagents, including molecular diagnostics and biochemical reagents, leveraging its proprietary technologies. It is also developing vaccines and immuno-oncology therapeutics for disease prevention and treatment. Genematrix possesses multiplex testing technology through key products for diagnosing sexually transmitted infections, tuberculosis, and human papillomavirus, facilitating its expansion into global markets.